(Q46448637)

English

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

scientific article published in June 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

0 references

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

Enrico Franceschi

object named as

Enrico Franceschi

4

0 references

7

object named as

Lauren E Abrey

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

author name string

Vincent A Miller

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

Neelam Shah

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

Daniel T Milton

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

language of work or name

0 references

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

number of pages

5

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

103

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

2344-2348

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21033

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21033

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15844174

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46448637&oldid=2112031892"